Crossmark

Radiomics combined with clinical characteristics predicted the progression-free survival time in first-line targeted therapy for advanced non-small cell lung cancer with EGFR mutation

Crossref DOI link: https://doi.org/10.1186/s13104-022-06019-x

Published Online: 2022-04-14

Published Print: 2022-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhu, Jian-man

Sun, Lei

Wang, Linjing

Zhou, Tong-Chong

Yuan, Yawei

Zhen, Xin

Liao, Zhi-Wei
Funding

Funding for this research was provided by:

the Guangzhou Key Medical Discipline Construction Project Fund and the Key Clinical Technology of Guangzhou (2019ZD17)

Guangdong Provincial Medical Scientific Research Fund Project (A2022213)

Guangzhou Key Medical Discipline Construction Project Fund (02-412-B205002-1004042)

Natural Science Foundation of Guangdong Province (2022A1515012104)
License Information

Text and Data Mining valid from 2022-04-14

Version of Record valid from 2022-04-14
More Information

Article History

Received: 26 November 2021

Accepted: 27 March 2022

First Online: 14 April 2022

Declarations

:

: This study was approved by the ethics review board of the Affiliated Cancer Hospital of Guangzhou Medical University, considered as a retrospective study and therefore waived the need for patient informed consent.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below